Search This Blog

Tuesday, March 3, 2026

Theravance end program after Phase 3 CYPRESS trial fails primary endpoint, launches strategic review

 


  • Phase 3 CYPRESS trial of ampreloxetine failed to meet its primary endpoint, leading management to terminate the program.
  • Company will conduct an accelerated strategic review that may include a sale of the company.
  • Theravance plans major restructuring aimed at cutting costs by about 60%.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)